News | January 29, 2026
Roche’s investigational obesity drug CT-388 delivers dramatic weight loss in Phase II trial
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
Company to launch product after the expiry of semaglutide patent in India
This certification paves the way for CORONA's entry into five EAEU member nations- Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan-under a B2B business model
Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited
The clearance marks a major step in Diabeloop’s ambition to become a central partner for insulin pump manufacturers and expand access to automated insulin delivery in the US market
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
Subscribe To Our Newsletter & Stay Updated
